EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Impact of obinutuzumab alone and in combination for follicular lymphoma

Maryam Sarraf Yazdy, Bruce D Cheson

Blood and Lymphatic Cancer: Targets and Therapy · 2017

DOI: 10.2147/blctt.s114173 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Blood and Lymphatic Cancer: Targets and Therapy, 2017. Verfasst von Maryam Sarraf Yazdy und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, USA, bdc@georgetown.edu. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

MRDfollicular lymphomamonoclonal antibodyobinutuzumab

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, USA, bdc@georgetown.edu.

Zitieren

APA

Sarraf Yazdy, M., & Cheson, B. D. (2017). Impact of obinutuzumab alone and in combination for follicular lymphoma. Blood and Lymphatic Cancer: Targets and Therapy. https://doi.org/10.2147/blctt.s114173

Vancouver

Sarraf Yazdy M, Cheson BD. Impact of obinutuzumab alone and in combination for follicular lymphoma. Blood and Lymphatic Cancer: Targets and Therapy. 2017. doi:10.2147/blctt.s114173

BibTeX
@article{SarrafYazdy2017,
  author = {Sarraf Yazdy, Maryam and Cheson, Bruce D},
  title = {Impact of obinutuzumab alone and in combination for follicular lymphoma},
  journal = {Blood and Lymphatic Cancer: Targets and Therapy},
  year = {2017},
  doi = {10.2147/blctt.s114173}
}
Kostenlos starten →